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Abstract: Vitamin C may reduce inflammation and is inversely associated with mortality in the
general population. We investigated the association of plasma vitamin C with all-cause mortality in
renal transplant recipients (RTR); and whether this association would be mediated by inflammatory
biomarkers. Vitamin C, high sensitive C-reactive protein (hs-CRP), soluble intercellular cell adhesion
molecule 1 (sICAM-1), and soluble vascular cell adhesion molecule 1 (sVCAM-1) were measured in a
cohort of 598 RTR. Cox regression analyses were used to analyze the association between vitamin C
depletion (≤28 µmol/L; 22% of RTR) and mortality. Mediation analyses were performed according to
Preacher and Hayes’s procedure. At a median follow-up of 7.0 (6.2–7.5) years, 131 (21%) patients died.
Vitamin C depletion was univariately associated with almost two-fold higher risk of mortality (Hazard
ratio (HR) 1.95; 95% confidence interval (95%CI) 1.35–2.81, p < 0.001). This association remained
independent of potential confounders (HR 1.74; 95%CI 1.18–2.57, p = 0.005). Hs-CRP, sICAM-1,
sVCAM-1 and a composite score of inflammatory biomarkers mediated 16%, 17%, 15%, and 32%
of the association, respectively. Vitamin C depletion is frequent and independently associated with
almost two-fold higher risk of mortality in RTR. It may be hypothesized that the beneficial effect of
vitamin C at least partly occurs through decreasing inflammation.
Keywords: renal transplant; vitamin C; mortality; inflammation; hs-CRP
1. Introduction
Renal transplantation is currently considered the “gold standard” treatment for end-stage renal
disease (ESRD) patients, since it offers superior survival, quality of life and cost-effectiveness compared
to chronic dialysis treatment [1–8]. Nevertheless, survival of renal transplant recipients (RTR) is
significantly lower than of age-matched controls in the general population [9].
It is worth noting that after renal transplantation a long-term ongoing inflammatory status
persists [10–12]. It was recently reported that higher inflammatory status is associated with an
increased risk of mortality in RTR [13]. In keeping with this finding, high sensitive C-reactive protein
(hs-CRP), an established marker of inflammation, has been associated with increased risk of mortality in
RTR [14,15]. It has been reported that vitamin C (ascorbic acid) is negatively correlated with C-reactive
protein [16]. Both oral and high-dose intravenous vitamin C therapy reduced CRP levels and other
pro-inflammatory cytokines [17–19]. Furthermore, vitamin C has been shown to be inversely associated
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with risk of all-cause mortality in the general population [20–24]. However, to date the role and
long-term effects of vitamin C status on inflammatory biomarkers and adverse outcomes such as
all-cause mortality in stable RTR remains unexplored, yet the results are of significant interest.
In this study, we aimed to investigate prospectively whether plasma vitamin C concentration and,
specifically, its depletion (≤28 µmol/L) [25–31] is associated with risk of all-cause mortality in RTR.
In addition, we aimed to evaluate whether a putative association between vitamin C concentration
and risk of all-cause mortality in RTR would be mediated by inflammatory parameters such as hs-CRP,
soluble intercellular cell adhesion molecule 1 (sICAM-1) and soluble vascular cell adhesion molecule 1
(sVCAM-1).
2. Materials and Methods
2.1. Study Design
In this prospective cohort study, all adult RTR who survived with a functioning allograft beyond
the first year after transplantation, and without known or apparent systemic illnesses (i.e., malignancies,
opportunistic infections) were invited to participate during their next visit to the outpatient clinic.
From a total of 847 eligible RTR, 606 (72%) patients signed informed consent. The group that did not
sign informed consent was comparable with the group that signed informed consent with respect to
age, sex, body mass index (BMI), serum creatinine, creatinine clearance, and proteinuria. Baseline
data was collected between August 2001 and July 2003 at a median 5.9 (interquartile range (IQR):
2.6–11.4) years after renal transplantation. For the statistical analyses we excluded patients missing
plasma vitamin C measurements (n = 8), resulting in 598 RTR eligible for analyses. Use of vitamin C
supplements or multivitamin supplements containing vitamin C were documented in all RTR. The
Institutional Review Board approved the study protocol (METc 2001/039). The clinical and research
activities being reported are consistent with the Principles of the Declaration of Istanbul as outlined in
the ‘Declaration of Istanbul on Organ Trafficking and Transplant Tourism’.
The primary endpoint of this study was RTR mortality of all cause in nature. The continuous
surveillance system of the outpatient program ensures up-to-date information on patient status.
We contacted general practitioners or referring nephrologists in case the status of a patient was
unknown. There was no loss due to follow-up.
2.2. Renal Transplant Characteristics
Relevant transplant characteristics including both donor and recipient age and gender, as well
as transplant information were extracted from the Groningen Renal Transplant Database, which
contains information about all renal transplantations that have been performed at the University
Medical Centre Groningen since 1986. Smoking status was obtained using a self-report questionnaire.
Smoking behavior was classified as never, former or current smoker. Cardiovascular disease history
was considered positive if participants had a myocardial infarction, transient ischemic attack or
cerebrovascular accident. Data on cumulative dose of steroids, incidence of acute rejection episodes and
use of mechanistic target of rapamycin (m-TOR) inhibitors were retrieved from individual patient files.
Cumulative dose of prednisolone was calculated as the sum of maintenance dose of prednisolone until
inclusion and the dose of prednisolone or methylprednisolone required for treatment of acute rejection
(a conversion factor of 1.25 was used to convert methylprednisolone dose to dose of prednisolone).
2.3. Measurements
Body mass index was calculated as weight in kilograms, divided by height in meters squared.
Waist circumference was measured on bare skin midway between the iliac crest and the 10th rib.
Blood pressure was measured as the average of three automated (Omron M4, Omron Europe B.V.,
Hoofddorp, The Netherlands) measurements with 1-min intervals after a 6-min rest in supine position.
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Blood was drawn in the morning after an 8 to 12 h overnight fasting period, which included
no medication intake. In order to measure plasma vitamin C concentration, blood was directly after
phlebotomy transferred to the laboratory on ice, deproteinized and stored in the dark at –20 ◦C until
analysis. For quantitative measurement ascorbic acid is enzymatically transformed to dehydroascorbic
acid, which in turn is derivatized to 3-(1,2-dihydroxyethyl)furo-[3,4-b]quinoxaline-1-one. Then,
reversed phase liquid chromatography with fluorescence detection is applied (excitation 355 nm,
emission 425 nm). Serum high sensitive C-reactive protein was assessed as described before [32].
Plasma sICAM-1 and sVCAM-1 concentrations were measured by enzyme-linked immunosorbent
assay kits (Diaclone Research, Besançon, France). Serum creatinine concentrations were determined
using the Jaffé method (MEGA AU510, Merck Diagnostica, Darmstadt, Germany). Total cholesterol
was determined using the cholesterol oxidase-phenol aminophenazone method (MEGA AU510,
Merck Diagnostica, Darmstadt, Germany), and serum triglycerides were determined with the
glycerol-3-phosphate oxidase-phenol aminophenazone method (MEGA AU510, Merck Diagnostica,
Darmstadt, Germany). High density lipoprotein (HDL)-cholesterol was determined with the cholesterol
oxidase-phenol aminophenazone method on a Technikon RA-1000 (Bayer Diagnostics, Mijdrecht,
The Netherlands), and low density lipoprotein (LDL)-cholesterol was calculated using the Friedewald
formula [33]. Plasma glucose was determined by the glucose-oxidase method (YSI 2300 Stat plus,
Yellow Springs, OH, USA). Glycated hemoglobin (HbA1c) was determined by high performance liquid
chromatography (VARIANTTM HbA1c Program with Bio-Rad CARIANT Hb Testing System, Bio-Rad,
Hercules, CA, USA).
According to a strict protocol all RTR were asked to collect a 24-hour urine sample during the
day before their visit to the outpatient clinic. Urine was collected under oil and chlorohexidine was
added as an antiseptic agent. Proteinuria was defined as urinary protein excretion >0.5 g/24 h. Renal
function was assessed by estimated Glomerular Filtration Rate (eGFR) applying the Chronic Kidney
Disease Epidemiology Collaboration equation [34].
2.4. Statistical Analysis
Data were analyzed using IBM SPSS software version 23.0 (SPSS Inc., Chicago, IL, USA),
STATA 12.0 (StataCorp LP, College Station, TX, USA) and R version 3.2.3. In all analyses, a 2-sided
p < 0.05 was considered significant. Hazard ratio (HR) are reported with 95% confidence interval (CI).
Continuous variables were summarized using mean (standard deviation (SD)) for normally distributed
data, whereas skewed distributed variables are given as median (IQR); percentages were used to
summarize categorical variables. Linear regression analyses were performed to evaluate the association
of plasma vitamin C concentration with recipient-related and transplantation-related characteristics.
Natural log transformation was used for analyses of variables with a skewed distribution.
A log-rank test was run to determine if there were differences in the survival distribution
between plasma vitamin C status (depleted and non-depleted; ≤ or >28 µmol/L, respectively)
of RTR. To analyze whether plasma vitamin C concentration is independently associated with
mortality, we performed Cox-proportional hazards regression analyses. For these analyses plasma
vitamin C concentration was used as categorical variable according to depleted or not depleted
concentration [25,26,28–30]; and as continuous variable (2 base of log-transformed values to achieve
a normal distribution), in order to obtain the best fitting model. First, we performed univariate Cox
regression analyses. Hereafter, we adjusted for age and sex (Model 2); for eGFR, proteinuria, primary
renal diseases and time since transplantation (Model 3). To avoid inclusion of too many variables
for the number of events, further models were performed with additive adjustments to model 3.
We performed additional adjustments for smoking status and alcohol use (Model 4); for diabetes
mellitus (Model 5); and for systolic blood pressure, BMI, serum HDL cholesterol and triglycerides
concentration (Model 6); and for use of calcineurin inhibitors, use of antimetabolites, use of m-TOR
inhibitors, use of induction therapy, and cumulative dose of prednisolone (model 7).
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As secondary analyses, we also performed classic mediation analyses according to Preacher
and Hayes [35,36], which are based on logistic regression; to establish whether hs-CRP sICAM-1 and
sVCAM-1 concentrations, separately and combined (sum of individual Z scores of hs-CRP + sICAM-1 +
sVCAM-1), mediated the association between plasma vitamin C concentration and all-cause mortality.
These analyses allow for testing significance and magnitude of mediation.
3. Results
3.1. Baseline Characteristics
A total of 598 stable RTR were included (mean age 51 ± 12 years, 54% male, 96% caucasian) at
5.9 (2.6–11.4) years after transplantation. Among them 133 (22%) RTR were vitamin C depleted.
None of the patients used vitamin C supplements or multivitamin supplements containing
vitamin C. Median (IQR) plasma vitamin C, hs-CRP, sICAM-1 and sVCAM-1 concentration were
44 (31–55) µmol/L, 2.0 (0.7–4.8) mg/L, 602 (514–720) ng/L, and 965 (772–1196) ng/L, respectively.
Mean eGFR was 47± 15 mL/min/1.73 m2, 166 (28%) participants had proteinuria. Additional baseline
characteristics are shown in Table 1.





Std. β p Value
No. of patients 598 - -
Vitamin C, µmol/L 44 (31–55) - -
Demographics
Age, years 51 ± 12 −0.05 * 0.23 *
Sex (male), n (%) 328 (54) −0.18 * <0.001 *
Ethnicity (caucasian), n (%) 577 (96) −0.02 0.60
Body Composition
Body surface area, m2 1.87 ± 0.19 −0.04 0.22
Body mass index, kg/m2 26.0 ± 4.3 −0.08 0.06
Primary Renal Diseases −0.02 0.61
Primary glomerulonephritis, n (%) 169 (28) - -
Glomerulonephritis due to vascular or autoimmune disease, n (%) 36 (6) - -
Tubulointerstitial nephritis and pyelonephritis, n (%) 92 (15) - -
Polycystic kidney disease, n (%) 106 (18) - -
Dysplasia and hypoplasia, n (%) 21 (4) - -
Renovascular disease, n (%) 32 (5) - -
Diabetic nephropathy, n (%) 22 (4) - -
Hereditary diseases and other, n (%) 117 (20) - -
Tobacco Use −0.08 0.06
Never smoker, n (%) 214 (35) - -
Ex-smoker, n (%) 251 (42) - -
Current smoker, n (%) 131 (21) - -
Blood Pressure
Systolic blood pressure, mmHg 153 ± 22 −0.11 0.004
Diastolic blood pressure, mmHg 89 ± 9 −0.11 0.01
Use of ACE-inhibitor or aII-antagonist, n (%) 201 (33) 0.07 0.11
Use of beta-blocker, n (%) 368 (61) −0.07 0.11
Prior History of CV Disease
History of MI, n (%) 48 (8) −0.01 0.75
History of TIA/CVA, n (%) 32 (5) −0.04 0.36





Std. β p Value
Transplantation
Time since transplantation, years 5.9 (2.6–11.4) 0.20 <0.001
Dialysis vintage, months −0.14 0.001
141 (24) - -
1–5 years 363 (61) - -
>5 years 94 (16) - -
Deceased donor, n (%) 515 (86) 0.02 0.61
Immunosuppressive Therapy
Prednisolone, mg/day 10.0 (7.5–10.0) −0.11 0.008
Use of calcineurin inhibitors −0.09 0.02
Cyclosporine, n (%) 386 (65) - -
Tacrolimus, n (%) 84 (14) - -
None, n (%) 128 (21) - -
Use of antimetabolites −0.06 0.19
Azathioprine, n (%) 194 (32) - -
Mycophenolic acid, n (%) 247 (41) - -
None, (%) 157 (26) - -
Use of m-TOR inhibitors, n (%) 10 (2) −0.10 0.02
Induction therapy −0.20 <0.001
Anti-thymocyte globulin, n (%) 70 (12) - -
Muromonab-CD3 , n (%) 26 (4) - -
Anti-CD25 monoclonal antibodies, n (%) 10 (2) - -
None, n (%) 492 (82) - -
Acute rejection treatment −0.13 0.03
High doses of steroids, n (%) 186 (31) - -
Other rejection therapy, n (%) 82 (14) - -
Cumulative dose of prednisolone, grams 21.3 (11.3–37.9) 0.21 <0.001
Ischemia Times
Cold ischemia time, hours 22 (15–27) 0.01 0.75
Total warm ischemia, minutes 35 (30–45) 0.02 0.72
Renal Allograft Function
eGFR, mL/min/1.73 m2 47 ± 15 0.11 0.009
Urinary protein excretion, g/24 h 0.2 (0.0–0.5) −0.06 0.22
Proteinuria (>0.5 g/24 h), n (%) 166 (27) −0.11 0.006
Inflammation
hs-CRP, mg/L 2.0 (0.7–4.8) −0.19 <0.001
sICAM-1, ng/L 602 (514–720) −0.17 <0.001
sVCAM-1, ng/L 965 (772–1196) −0.16 <0.001
Lipids
Total colesterol, mmol/L 5.6 ± 1.0 0.05 0.24
HDL colesterol, mmol/L 1.0 ± 0.3 0.11 0.004
LDL cholesterol, mmol/L 3.5 ± 0.9 0.07 0.09
Triglycerides, mmol/L 1.9 (1.4–2.6) −0.13 0.001
Use of statins, n (%) 295 (49) 0.06 0.13
Oxidative Stress
Gamma glutamate, U/L 24 (18–39) −0.10 0.02
Alkaline phophatase, U/L 72 (57–94) −0.21 <0.001
Uric acid, mmol/L 0.4 (0.3–0.5) −0.08 0.05





Std. β p Value
Glucose Homeostasis
Insulin, µU/mL 11 (7–16) −0.08 0.04
Glucose, mmol/L 4.5 (4.1–5.0) −0.07 0.06
HbA1c, % 6.5 ± 1.0 −0.12 0.002
Diabetes, n (%) 105 (17) −0.11 0.008
Hematology
Leukocyte count, x 109/L 8.5 ± 2.4 −0.03 0.42
Hemoglobin, mmol/L 8.5 ± 0.9 0.01 0.77
Platelets count, x 109/L 231 ± 69 −0.02 0.56
* Unadjusted. Abbreviations: ACE, angiotensin converting enzyme; CV, cardiovascular; CVA, cardiovascular
accident; eGFR, estimated Glomerular Filtration Rate; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein;
hs-CRP, high-sensitive C reactive protein; LDL; low-density lipoprotein; m-TOR, mechanistic target of rapamycin;
MI, myocardial infarction; sICAM-1, soluble intercellular cell adhesion molecule 1; sVCAM-1, soluble vascular
cell adhesion molecule 1; TIA, transient ischemic attack; RTR, renal transplant recipients. Baseline characteristics
normally distributed are summarized using means (SD), whereas skewed distributed variables are given as medians
(IQR); percentages were used to summarize categorical variables. Multivariate linear regression analyses were
performed to obtain a p value of potential associations of baseline characteristics of renal transplant recipients with
plasma vitamin C concentration.
3.2. Association of Plasma Vitamin C Concentration with Clinical Variables
Age- and sex-adjusted plasma vitamin C concentration was associated with hs-CRP
(std. β = −0.19; p < 0.001), sICAM-1 (std. β = −0.17; p < 0.001) and sVCAM-1 (std. β = −0.16;
p < 0.001) concentrations. Moreover, alkaline phosphatase (std. β = −0.21; p < 0.001) and gamma
glutamate (std. β =−0.10; p = 0.02) were associated with plasma vitamin C concentration. Furthermore,
vitamin C was significantly associated with HbA1c (std. β = −0.12; p = 0.002), diabetes (std. β = −0.11;
p = 0.008), and insulin concentration (std. β =−0.08; p = 0.04). Likewise, eGFR (std. β = 0.11; p = 0.009),
systolic blood pressure (std. β = −0.11; p = 0.004) and diastolic blood pressure (std. β = −0.11;
p = 0.01) were associated to vitamin C concentration. Dialysis vintage (std. β = −0.14; p = 0.001) and
immunosuppressive therapy including use of calcineurin inhibitors (std. β = −0.09; p = 0.02), use of
m-TOR inhibitors (std. β =−0.10; p = 0.02), induction therapy (std. β =−0.20; p < 0.001), acute rejection
treatment (std. β = −0.13; p = 0.03), and cumulative dose of prednisolone (std. β = −0.21; p ≤ 0.001),
were associated to plasma vitamin C concentration (Table 1).
3.3. Prospective Analyses
During a median follow-up of 7.0 (6.2–7.5) years, 131 (21%) patients died. 32% of plasma vitamin C
depleted patients died, whereas among non-depleted patients 18% died. The survival distributions
between depleted and non-depleted RTR were significantly different (log-rank test p < 0.001).
A Kaplan-Meier curve for all-cause mortality according to plasma vitamin C status is shown in Figure 1.
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  HR  95% CI  p  Reference  HR  95% CI  p 
Model 1  1.95  1.35–2.81  <0.001  1.00  0.71  0.59–0.87  0.001 
Model 2  1.92  1.33–2.77  0.001  1.00  0.74  0.61–0.90  0.002 
Model 3  1.88  1.28–2.76  0.001  1.00  0.76  0.62–0.94  0.011 
Model 4  1.91  1.30–2.82  0.001  1.00  0.76  0.62–0.94  0.012 
Model 5  1.80  1.22–2.65  0.003  1.00  0.79  0.64–0.98  0.030 
Model 6  1.70  1.15–2.52  0.008  1.00  0.79  0.63–0.98  0.030 




Model 4: Model 3 + adjustment  for  smoking and alcohol use. Model 5: Model 3 + adjustment  for 
diabetes mellitus. Model 6: Model 3 + adjustment for systolic blood pressure, body mass index, high 
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Figure 1. Kaplan-Meier curve for all-cause mortality according to plasma vitamin C status (depleted
versus non-depleted) among renal transplant recipients. Vitamin C depleted: ≤28 µmol/L; Vitamin C
non-depleted: >28 µmol/L.
Results of univariate and multivariate Cox-proportional hazard regre sion analyses are shown
in Table 2. Prospective analyses of the association between vitamin C concentration with all-cause
mortality s t t l vitamin C depleted RTR had an almost double risk of mortality (HR 1.95;
95% CI 1.35–2.81, p < 0.001). This association was independent of further adjustment for potential
c nfounders, with e.g., an HR of 1.88; 95% CI 1.28–2.76, p = 0.001 after adjustment for age, s x,
GFR, proteinuria, prima y renal disease, tim sinc transplantation and dialysis vintage. Further
adjustment for other potential confounders (i.e., smoking and alc hol st tus, diabetes mellitus, systolic
blood pressure, BMI, HDL cholesterol and triglycerid s concent ation, use of cal i eurin inhibitors,
use of antimetabolites, use of m-TOR inhibitors, use of induction therapy, a cumulative dose of
prednisolone) did not materially alter the associ tion.
Table 2. Prospective analysis of plasma vitamin C on all-cause mortality in RTR.







HR 95% CI p Reference HR 95% CI p
Model 1 1.95 1.35–2.81 <0.001 1.00 0.71 0.59–0.87 0.001
Model 2 1.92 1.33–2.77 0.001 1.00 0.74 0.61–0.90 0.002
Model 3 1.88 1.28–2.76 0.001 1.00 0.76 0.62–0.94 0.011
Model 4 1.9 1.30–2.82 .001 . 0 0.76 0.62–0.94 0.012
Model 5 1.80 1.22–2.65 0.003 1.00 0.79 0.64–0.98 0.030
Model 6 1.70 1.15–2.52 0.008 1.00 0.79 0.63–0.98 0.030
Model 7 1.74 1.18–2.57 0.005 1.00 0.78 0.63–0.97 0.024
Abbreviations: RTR, renal transplant recipients; HR, hazard ratio; CI, confidence interval. Model 1: Univariate.
Model 2: Age and sex adjusted. Model 3: Model 2 + adjustment for estimated Glomerular Filtration Rate, proteinuria,
primary renal disease, time since transplantation, and dialysis vintage. Model 4: Model 3 + adjustment for smoking
and alcohol use. Model 5: Model 3 + adjustment for diabetes mellitus. Model 6: Model 3 + adjustment for systolic
blood pressure, body mass index, high density lipoprotein cholesterol, and triglycerides concentration. Model 7:
Model 3 + adjustment for use of calcineurin inhibitors, use of antimetab lites, use f m-TOR inhibitors, use of
induction therapy, and cumulative dose of prednisolone.
Vitamin C as a continuou variable was univariately associated wit all-cause mortality (HR 0.71;
95% CI 0.59–0.87, p = 0.001), with the point estimate of the HR below 1.00 indicating that risk decreases
with increasing vitamin C concentrations. In multivariable analysis, after adjustment for potential
confounders the association remained, with a HR of 0.76; 95% CI 0.62–0.94, p = 0.011 (Table 2; Figure 2).






Figure  2. Association of plasma vitamin C with  risk of all‐cause mortality. The  line  in  the graph 
represents the hazard ratio. The grey area represents the 95% confidence interval of the hazard ratio. 
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hs‐CRP  Indirect effect (ab path)  −0.016 (−0.036; −0.004)  16% *** Total effect (ab + c’ path)  −0.103 (−0.189; −0.010) 
sICAM‐1  Indirect effect (ab path)  −0.018 (−0.043; −0.003)  17% *** Total effect (ab + c’ path)  −0.103 (−0.194; −0.016) 







Abbreviations:  hs‐CRP,  high  sensitive  C‐reactive  protein;  sICAM‐1,  soluble  intercellular  cell 
adhesion molecule  1;  sVCAM‐1,  soluble vascular  cell  adhesion molecule  1; RTR,  renal  transplant 
recipients; CI, confidence interval. * The coefficients of the indirect ab path and the total ab + c’ path 
are  standardized  for  the  standard  deviations  of  the  potential  mediators,  plasma  vitamin  C 
concentration  and  outcomes.  ** All  coefficients  are  adjusted  for  age,  sex,  estimated  Glomerular 
Filtration Rate, time since transplantation, primary renal disease, and proteinuria. *** The size of the 
Figure 2. Association of plasma vitamin C with risk of all-cause mortality. The line in the graph
represents the hazard ratio. The grey area represents the 95% onfidence in erval of th hazard ratio.
3.4. Mediation Analyses
In mediation analyses according to the procedures of Preacher and Hayes [35,36], hs-CRP, sICAM-1
and sVCAM-1 concentration were significant mediators (p value for indirect effect <0.05) in the
association of vitamin C concentration with mortality. The magnitude of the mediating effects of
hs-CRP, sICAM-1 and sVCAM-1 accounted 16, 17 and 15%, respectively. Furthermore, combined
inflammatory biomarkers mediated 32% on the association of plasma vitamin C concentration with
risk of all-cause mortality in RTR (Table 3; Figure A1).
Table 3. Mediating effects of hs-CRP, sICAM-1, sVCAM-1 separately and combined on the association










Indirect effect (ab path) −0.016 (−0.036; −0.004)
16% **Total effect (ab + c’ path) −0.103 (−0.189; −0.010)
sICAM-1
Indirect effect (ab path) −0.018 (−0.043; −0.003)
17% ***Total effect (ab + c’ path) −0.103 (−0.194; −0.016)
sVCAM-1
Indirect effect (ab path) −0.015 (−0.040; −0.003)
15% ***Total effect (ab + c’ path) −0.103 (−0.200; −0.015)
Combined inflammation
Indirect effect (ab path) −0.033 (−0.065; −0.012)
32% ***Total effect (ab + c’ path) −0.103 (−0.191; −0.013)
Abbreviations: hs-CRP, high sensitive C-reactive protein; sICAM-1, soluble intercellular cell adhesion molecule 1;
sVCAM-1, soluble vascular cell adhesion molecule 1; RTR, renal transplant recipients; CI, confidence interval.
* The coefficie ts of the indirect ab path and the total ab + c’ path ar standardized for the standard deviations of the
potential mediators, plasma vitamin C concentration and outcomes. ** All coefficients are adjusted for age, sex,
estimated Glomerular Filtration Rate, time since transplantation, primary renal disease, and proteinuria. *** The size
of the significant mediated effect is calculated as the standardized indirect effect divided by the standardized total
effect multiplied by 100. † 95% confi ence int rv ls for the indirect and tot l effects were bias-corrected confidence
intervals after running 2000 bootstrap samples.
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4. Discussion
This study showed, first, that vitamin C depletion was common in a stable outpatient population
of RTR, and that plasma vitamin C concentration was independently and inversely associated with risk
of all-cause mortality in RTR. Particularly, plasma vitamin C depletion was detrimental, as depicted by
an almost two fold higher risk of mortality within patients that had plasma vitamin C concentration
equal or lower than 28 µmol/L [25–31]. Importantly, adjustment for several potential confounders did
not alter the association. Of note, the association between vitamin C and mortality has been previously
reported in the general population [20–24]; however, to our knowledge, this is the first study that
examines the association of plasma vitamin C concentration with all-cause mortality in RTR and,
specifically, the effect of plasma vitamin C depletion on patient survival after renal transplantation.
Further, we found that combined inflammatory biomarkers mediated the robust proportion
of about one third of the association of plasma vitamin C concentration with all-cause mortality.
Notwithstanding that the underlying mechanisms leading to significantly lower survival of RTR
compared to age-matched controls in the general population [9] are not completely understood, it is
noteworthy that a long-term ongoing inflammatory status remains after renal transplantation [10–12].
Indeed, Abedini et al. [15], reported that in a cohort of 2102 RTR, over a follow-up period
of 5–6 years, hs-CRP was independently associated with all-cause mortality in RTR. Likewise,
Winkelmayer et al. [14] found that, at a median follow-up of 7.8 years after renal transplantation
in a cohort of 438 RTR, CRP levels of more than 5 mg/L were associated with an 83% greater mortality
risk compared with lower levels of this inflammatory marker. These observations are in agreement
with our findings and support the influence of low-grade ongoing inflammation on patient survival
after renal transplantation. On the basis of these findings and currently available literature [10–15]
one might propose that inflammation plays a major role in the underlying mechanisms leading to
decreased survival after renal transplantation. Finally, taking into account that we found that vitamin C
concentration was inversely associated with inflammatory biomarkers, which is in agreement with
previous reports [16–19], we hypothesize that the beneficial effect of adequate vitamin C status on
survival of RTR is at least partly mediated by diminishing inflammatory status.
On the basis of current findings it is expected that reduction of inflammation through vitamin C
supplementation, could be an approach to encourage protection against tissue injury and improve
current survival rates of RTR. A recent randomized controlled trial evaluated the effect of oral vitamin C
supplementation (200 mg/day during 3 months) on inflammatory status among 100 maintenance
hemodialysis patients [37]. Compared with patients that did not receive supplementation, a significant
decrease of hs-CRP levels was found among the vitamin C supplemented group. Moreover, the hs-CRP
levels returned to their original state after the supplementation was withdraw. In turn, Atallah et al.
reported the effect of intravenous vitamin C supplementation (300 mg each dialysis session) on
inflammatory parameters in hemodialysis patients. This study showed that CRP levels between
baseline and 6 months were significantly decreased in the supplemented, but not in the control
group [38]. Nevertheless, to our knowledge no randomized controlled trial has been reported
evaluating the effect of vitamin C supplementation strategies on inflammatory biomarkers or
prospective outcomes in RTR.
The strength of this study lays in its prospective design; and that it comprises a large cohort of
stable RTR which were closely monitored by regular check-up in the outpatient clinic, which gives
complete information on patient status. A limitation is that we did not have repeated measurements of
vitamin C levels. However, it should be realized that if intra-individual variability of vitamin C is taken
into account, the predictive properties become stronger. The higher the intra-individual day-to-day
variation of vitamin C would be, the greater one would expect the benefit of repeated measurement
for prediction of outcomes [39,40]. Moreover, as with any observational study, reversed causation
or unmeasured confounding may occur, despite the substantial number of potentially confounding
factors for which we adjusted. As we have no data on nutrition, we cannot exclude the possibility
that the association exists as a consequence of vitamin C being a marker of poor nutrition. Finally,
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since this is a single center study; the predictive value of vitamin C on mortality in RTR requires to be
confirmed within a multicenter study.
5. Conclusions
In conclusion, plasma vitamin C depletion is common in stable RTR, and is independently and
inversely associated with all-cause mortality after renal transplantation. Since hs-CRP, sICAM-1 and
sVCAM-1 were found to be important mediators in the association between vitamin C and all-cause
mortality, we hypothesize that the beneficial effect of vitamin C would occur through decreasing
inflammatory status. On the basis of the current findings, further research is needed to evaluate
whether vitamin C supplementation could be a therapeutic strategy in order to increase survival after
renal transplantation. The present study should encourage the design of multicenter, randomized,
double-blind, placebo-controlled trial, aimed to test the efficacy of this novel therapeutic strategy.
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Figure A1. Mediation analysis of combined score between hs-CRP, sICAM-1 and sVCAM-1 on the
associati n of plasma vitamin C conce tration with all-cause mortality. a, b and are the standardized
regression coefficients between variables. The indirect effect (through a potential mediator) is calculated
as a × b. Total effect (c) is a × b + c’. Magnitude of mediation is calculated as indirect effect divided by
total effect.
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